 Home > Medical News > Latest Medical News > One year later, the clinical remission rate was significantly improved. AbbVie JAK inhibitor reached the phase 3 clinical endpoint

One year later, the clinical remission rate was significantly improved. AbbVie JAK inhibitor reached the phase 3 clinical endpoint

 Last Update: 2021-08-10
 Source: Internet
 Author: User

Tags

places study abroad

dextroamphetamine 15 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AbbVie announced today that its JAK inhibitor upadacitinib has achieved the primary and all secondary endpoints of clinical remission in a Phase 3 clinical trial of maintenance therapy for the treatment of ulcerative colitis

In this study, adult patients with moderate to severe ulcerative colitis first received induction therapy with upadacitinib (45 mg) for 8 weeks

In addition to reaching the primary endpoint of the trial, upadacitinib also met all secondary endpoints, including endoscopic improvement at week 52, histology-endoscopic mucosal improvement (HEMI), and clinical conditions without glucocorticoid treatment Ease

▲The efficacy results of the maintenance treatment phase 3 clinical trial at week 52 (picture source: reference [1])

Ulcerative colitis is a chronic, systemic, and inflammatory disease caused by inflammation of the large intestine.

Upadacitinib was discovered and developed by AbbVie scientists.

Note: The original text has been deleted

Reference materials:

[1] Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.